ES2293223T3 - Composiciones enantiomericas de anfetamina para el tratamiento de adhd. - Google Patents

Composiciones enantiomericas de anfetamina para el tratamiento de adhd. Download PDF

Info

Publication number
ES2293223T3
ES2293223T3 ES04709870T ES04709870T ES2293223T3 ES 2293223 T3 ES2293223 T3 ES 2293223T3 ES 04709870 T ES04709870 T ES 04709870T ES 04709870 T ES04709870 T ES 04709870T ES 2293223 T3 ES2293223 T3 ES 2293223T3
Authority
ES
Spain
Prior art keywords
amphetamine
release
day
isomer
pharmaceutical combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04709870T
Other languages
English (en)
Spanish (es)
Inventor
Richard A. Couch
A. Shire Pharmaceutical Development Inc. MICHAELS
Paul Hodgkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Canada Inc
Original Assignee
Shire Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Canada Inc filed Critical Shire Canada Inc
Application granted granted Critical
Publication of ES2293223T3 publication Critical patent/ES2293223T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES04709870T 2003-02-10 2004-02-10 Composiciones enantiomericas de anfetamina para el tratamiento de adhd. Expired - Lifetime ES2293223T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44579303P 2003-02-10 2003-02-10
US445793P 2003-02-10
US47392503P 2003-05-29 2003-05-29
US473925P 2003-05-29

Publications (1)

Publication Number Publication Date
ES2293223T3 true ES2293223T3 (es) 2008-03-16

Family

ID=32871959

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04709870T Expired - Lifetime ES2293223T3 (es) 2003-02-10 2004-02-10 Composiciones enantiomericas de anfetamina para el tratamiento de adhd.

Country Status (10)

Country Link
US (1) US20040220277A1 (cg-RX-API-DMAC7.html)
EP (1) EP1626709B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006517232A (cg-RX-API-DMAC7.html)
KR (1) KR20050119106A (cg-RX-API-DMAC7.html)
AT (1) ATE372112T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004210671A1 (cg-RX-API-DMAC7.html)
CA (1) CA2515394A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004008771T2 (cg-RX-API-DMAC7.html)
ES (1) ES2293223T3 (cg-RX-API-DMAC7.html)
WO (1) WO2004071501A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
EP1874274A2 (en) * 2005-04-06 2008-01-09 Mallinckrodt Inc. Matrix-based pulse release pharmaceutical formulation
WO2007041571A1 (en) * 2005-10-03 2007-04-12 Cambrex Charles City, Inc. Improved method of making amphetamine free base
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
US10463633B2 (en) * 2010-04-23 2019-11-05 Kempharm, Inc. Therapeutic formulation for reduced drug side effects
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
WO2013059676A1 (en) * 2011-10-21 2013-04-25 Subhash Desai Compositions for reduction of side effects
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
IL288554B2 (en) * 2016-02-24 2024-02-01 Chemapotheca LLC Controlled release of amphetamine, drug meters and dosage forms with abuse deterrence
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
CA3221280A1 (en) 2021-06-03 2022-12-08 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
CA3239514A1 (en) * 2021-12-09 2023-06-15 Matthew J. Baggott Specialized combinations for mental disorders or mental enhancement

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6056968A (en) * 1997-03-11 2000-05-02 Darwin Discovery Limited Pharmaceutical drug dosage forms providing different release rates
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
WO2000059481A1 (en) * 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
TWI291871B (en) * 2000-11-01 2008-01-01 Cognition Pharmaceuticals Llc Pharmaceutical compositions and use of amphetamine compounds for improving memory and learning
AU2003208170B2 (en) * 2002-02-28 2006-11-23 Birseck Pty Ltd Treatment of effect of chemicals with their ultradilute stereoisomers
AU2003231156A1 (en) * 2002-04-30 2003-11-17 Npd Llc Multi-phasic delivery via transmucosal absorption of appetite suppressants and craving reduction medicaments
US6913768B2 (en) * 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts

Also Published As

Publication number Publication date
KR20050119106A (ko) 2005-12-20
WO2004071501A1 (en) 2004-08-26
DE602004008771D1 (de) 2007-10-18
CA2515394A1 (en) 2004-08-26
HK1091117A1 (en) 2007-01-12
EP1626709B1 (en) 2007-09-05
DE602004008771T2 (de) 2008-06-12
ATE372112T1 (de) 2007-09-15
EP1626709A1 (en) 2006-02-22
US20040220277A1 (en) 2004-11-04
JP2006517232A (ja) 2006-07-20
AU2004210671A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
ES2644942T3 (es) Métodos y composiciones para el tratamiento del trastorno por déficit de atención
ES2229483T3 (es) Composiciones farmaceuticas para la liberacion controlada de sustancias activas.
EP1626709B1 (en) Enantiomeric amphetamine compositions for the treatment of adhd
US10881618B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
ES2547141T3 (es) Composiciones que comprenden anfetamina y lisdexanfetamina
ES2529455T3 (es) Sistema de administración de fármacos por dosis controladas
US9283214B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) Methods of treatment of attention deficit hyperactivity disorder
US20150110868A1 (en) Methods for treatment of attention deficit hyperactivity disorder
US20260027063A1 (en) Compositions for Treatment of Attention Deficit Hyperactivity Disorder
JP2008540437A (ja) キニーネを含有する制御放出調合剤
ES2303314T3 (es) Formulaciones de liberacion prolongada de dipiridamol y procedimiento para su preparacion.
US10292937B2 (en) Methods of treatment of attention deficit hyperactivity disorder
US10905652B2 (en) Compositions for treatment of attention deficit hyperactivity disorder
CA2709104A1 (en) Method and composition for treating a serotonin receptor-mediated condition
ES3064270T3 (en) Trimodal, precision-timed pulsatile release tablet
HK1091117B (en) Enantiomeric amphetamine compositions for the treatment of adhd
MXPA05008448A (en) Enantiomeric amphetamine compositions for the treatment of adhd